Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (803)	1/15/2000 4:59:00 PM
From: HoodBuilder	Read Replies (1) \| Respond to of 3158

An undiscovered biotech stock! I was recently exposed to Epix Medical (EPIX). This company is in P3 trials for an imaging agent used with MRIs. The product will replace the need for invasive angiograms in a large number of patients by allowing doctors to view cardio-vascular irregularities through 3D MRI. www.epixmed.com can explain in depth the history and goal of this product. They recently presented at the H&Q Biotech conference and were siad to be one of the most UNDER VALUED biotech stocks in attendence. A projected $2.00 run rate by 2003, this $12 dollar stock has plenty of upside. Do some DD it is very promising technology!

To: Biomaven who wrote (803)	1/16/2000 3:37:00 PM
From: Vector1	Read Replies (2) \| Respond to of 3158

Peter, BGEN one of my long term holds (I have been shifting BGEN shares to SEPR) should be in the hunt for small to midsized biotechs but I doubt they will pull the trigger looking instead to enter into partner deals. The question you posed is a good one. Will the bigger fish be able to psycologically deal with having to pay 2 or 3 time that of a year ago. The answer is they should because their own multiples have expanded. I for one hope SEPR remains independent. V1